{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:55:17Z","timestamp":1780527317236,"version":"3.54.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a large proportion of the patients with primary hyperparathyroidism (PHPT), a variable degree of osteopenia is the only relevant manifestation of the disease. Low bone mineral density (BMD) in patients with PHPT is an indication for surgical intervention because successful parathyroidectomy results in a dramatic increase in BMD. However, low BMD values are almost an invariable finding in elderly women with PHPT, who are often either unwilling or considered unfit for surgery. Bisphosphonates are capable of suppressing parathyroid hormone (PTH)-mediated bone resorption and are useful for the prevention and treatment of postmenopausal osteoporosis. In this pilot-controlled study, we investigated the effects of oral treatment with alendronate on BMD and biochemical markers of calcium and bone metabolism in elderly women presenting osteoporosis and mild PHPT. Twenty-six elderly patients aged 67\u201381 years were randomized for treatment with either oral 10 mg alendronate on alternate-day treatment or no treatment for 2 years. In the control untreated patients a slight significant decrease was observed for total body and femoral neck BMD, without significant changes in biochemical markers of calcium and bone metabolism during the 2 years of observation. Urine deoxypyridinoline (Dpyr) excretion significantly fell within the first month of treatment with alendronate, while serum markers of bone formation alkaline phosphatase and osteocalcin fell more gradually and the decrease became significant only after 3 months of treatment; thereafter all bone turnover markers remained consistently suppressed during alendronate treatment. After 2 years in this group we observed statistically significant increases in BMD at lumbar spine, total hip, and total body (+8.6 \u00b1 3.0%, +4.8 \u00b1 3.9%, and +1.2 \u00b1 1.4% changes vs. baseline mean \u00b1 SD) versus both baseline and control patients. Serum calcium, serum phosphate, and urinary calcium excretion significantly decreased during the first 3-6 months but rose back to the baseline values afterward. Increase in serum PTH level was statistically significant during the first year of treatment. These preliminary results may make alendronate a candidate as a supportive therapy in patients with mild PHPT who are unwilling or are unsuitable for surgery, and for whom osteoporosis is a reason of concern.<\/jats:p>","DOI":"10.1359\/jbmr.2001.16.1.113","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T03:05:53Z","timestamp":1146107153000},"page":"113-119","source":"Crossref","is-referenced-by-count":144,"title":["Effects of Oral Alendronate in Elderly Patients with Osteoporosis and Mild Primary Hyperparathyroidism"],"prefix":"10.1093","volume":"16","author":[{"given":"Maurizio","family":"Rossini","sequence":"first","affiliation":[{"name":"Riabilitazione Reumatologica, Ospedale di Valeggio, Universit\u00e0 di Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[{"name":"Riabilitazione Reumatologica, Ospedale di Valeggio, Universit\u00e0 di Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Isaia","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina Interna, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Sartori","sequence":"additional","affiliation":[{"name":"Istituto di Medicina Interna, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Braga","sequence":"additional","affiliation":[{"name":"Riabilitazione Reumatologica, Ospedale di Valeggio, Universit\u00e0 di Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[{"name":"Riabilitazione Reumatologica, Ospedale di Valeggio, Universit\u00e0 di Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020714121733500_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/0003-4819-83-3-365","article-title":"Back pain and vertebral crush fractures: An unemphasized mode of presentation for primary hyperparathyroidism","volume":"83","author":"Dauphine","year":"1975","journal-title":"Ann Intern Med"},{"key":"2024020714121733500_bib2","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1001\/archinte.1987.00370110079012","article-title":"What is the clinical significance of bone loss in primary hyperparathyroidism?","volume":"147","author":"Kockersberger","year":"1987","journal-title":"Arch Intern Med"},{"key":"2024020714121733500_bib3","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1999.14.10.1700","article-title":"Primary hyperparathyroidism and the risk of fracture: A population-based study","volume":"14","author":"Khosla","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020714121733500_bib4","first-page":"729","article-title":"Increased bone mineral density following parathyroidectomy in primary hyperparathyroidism","volume":"80","author":"Silverberg","year":"1995","journal-title":"J Clin Metab"},{"key":"2024020714121733500_bib5","first-page":"4007","article-title":"Vertebral osteopenia: A new indication for surgery in primary hyperparathyroidism","volume":"81","author":"Silverberg","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714121733500_bib6","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1210\/jcem.83.11.5249","article-title":"Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism","volume":"83","author":"Abdelhadi","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714121733500_bib7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"key":"2024020714121733500_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(99)00150-7","article-title":"Primary hyperparathyroidism: Short-term changes in bone remodeling and bone mineral density following parathyroidectomy","volume":"25","author":"Christiansen","year":"1999","journal-title":"Bone"},{"key":"2024020714121733500_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S8756-3282(99)00207-0","article-title":"Primary hyperparathyroidism: Effect of parathyroidectomy on regional bone mineral density in Danish patients: A three year follow up study","volume":"25","author":"Christiansen","year":"1999","journal-title":"Bone"},{"key":"2024020714121733500_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S8756-3282(99)00208-2","article-title":"Primary hyperparathyroidism: Whole-body bone mineral density in surgically treated Danish patients: A three-year follow-up study","volume":"25","author":"Christiansen","year":"1999","journal-title":"Bone"},{"key":"2024020714121733500_bib11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-114-7-593","article-title":"Diagnosis and management of asymptomatic hyperparathyroidism: Consensus development conference statement","volume":"114","author":"Consensus Development National Institutes of Health (NIH) Conference Panel","year":"1991","journal-title":"Ann Intern Med"},{"key":"2024020714121733500_bib12","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/0003-4819-100-5-633","article-title":"Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism","volume":"100","author":"Marcus","year":"1984","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"2024020714121733500_bib13","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1002\/jbmr.5650061426","article-title":"Estrogens and progestins in the management of primary hyperparathyroidism","volume":"6","author":"Marcus","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2024020714121733500_bib14","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198606053142304","article-title":"Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women","volume":"314","author":"Selby","year":"1986","journal-title":"N Engl J Med"},{"key":"2024020714121733500_bib15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jbmr.5650090410","article-title":"Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy","volume":"9","author":"McDermott","year":"1994","journal-title":"J Bone Miner Res"},{"key":"2024020714121733500_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF01623394","article-title":"Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: A preliminary report","volume":"6","author":"Diamond","year":"1996","journal-title":"Osteoporos Int"},{"key":"2024020714121733500_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"key":"2024020714121733500_bib18","first-page":"3487","article-title":"Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"81","author":"Guo","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714121733500_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-95-1-23","article-title":"Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism","volume":"95","author":"Shane","year":"1981","journal-title":"Ann Intern Med"},{"key":"2024020714121733500_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bmj.286.6365.587","article-title":"Drug treatment of primary hyperparathyroidism: Use of clodronate disodium","volume":"286","author":"Douglas","year":"1983","journal-title":"BMJ"},{"issue":"Suppl 1","key":"2024020714121733500_bib21","first-page":"S69","article-title":"Clodronate in the medical management of hyperparathyroidism","volume":"8","author":"Hamdy","year":"1987","journal-title":"Bone"},{"key":"2024020714121733500_bib22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2265.1990.tb00869.x","article-title":"Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: Effect on clinical status","volume":"32","author":"Schmidli","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024020714121733500_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2265.1990.tb00504.x","article-title":"Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: Effects of bisphosphonate treatment","volume":"33","author":"Adami","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024020714121733500_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-6009(08)80249-8","article-title":"Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone","volume":"25","author":"Adami","year":"1994","journal-title":"Bone Miner"},{"key":"2024020714121733500_bib25","first-page":"1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714121733500_bib26","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Enl J Med"},{"key":"2024020714121733500_bib27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024020714121733500_bib28","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024020714121733500_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"2024020714121733500_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"2024020714121733500_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"2024020714121733500_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"2024020714121733500_bib33","first-page":"265","article-title":"Dose-response relationships for alendronate treatment in osteoporotic elderly women","volume":"82","author":"Bone","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714121733500_bib34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1172\/JCI113725","article-title":"Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment","volume":"82","author":"Civitelli","year":"1988","journal-title":"J Clin Invest"},{"key":"2024020714121733500_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002239900713","article-title":"Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis","volume":"65","author":"Gonnelli","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"2024020714121733500_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/17453678909149275","article-title":"Increased fracture risk in hypercalcemia: Bone mineral content measured in hyperparathyroidism","volume":"60","author":"Larsson","year":"1989","journal-title":"Acta Orthop Scand"},{"key":"2024020714121733500_bib37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2796.1993.tb01017.x","article-title":"The risk of hip fractures in patients with primary hyperparathyroidism: A population-based cohort study with a follow-up of 19 years","volume":"234","author":"Larsson","year":"1993","journal-title":"J Intern Med"},{"key":"2024020714121733500_bib38","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.1992.00400230081014","article-title":"Risk of age-related fractures in patients with primary hyperparathyroidism","volume":"152","author":"Melton","year":"1992","journal-title":"Arch Intern Med"},{"key":"2024020714121733500_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0039-6060(05)80017-0","article-title":"Fracture incidence in postmenopausal women with primary hyperparathyroidism","volume":"118","author":"Kenny","year":"1995","journal-title":"Surgery"},{"key":"2024020714121733500_bib40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.7326\/0003-4819-109-12-959","article-title":"Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures","volume":"109","author":"Wilson","year":"1988","journal-title":"Ann Intern Med"},{"key":"2024020714121733500_bib41","first-page":"723","article-title":"Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism","volume":"80","author":"Silverberg","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020714121733500_bib42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-67-6-1294","article-title":"Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course","volume":"67","author":"Rao","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"2024020714121733500_bib43","first-page":"S97","article-title":"Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: Clinical course and considerations bearing on the need for surgical intervention","volume":"6","author":"Parfitt","year":"1991","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2001.16.1.113","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/16\/1\/113\/56606198\/5650160114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/16\/1\/113\/56606198\/5650160114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:01:22Z","timestamp":1710342082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/16\/1\/113-119\/7515825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2001,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2001.16.1.113","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2001,1,1]]},"published":{"date-parts":[[2001,1,1]]}}}